Alaunos Therapeutics (TCRT) Projected to Release Quarterly Earnings on Tuesday

Alaunos Therapeutics (NASDAQ:TCRT) will likely be releasing its Q3 2026 resultson Tuesday, November 17th. Analysts expect Alaunos Therapeutics to post earnings of ($15.75) per share for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Alaunos Therapeutics (NASDAQ:TCRT) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter.

Alaunos Therapeutics Trading Down 4.0%

Shares of NASDAQ:TCRT opened at $1.67 on Tuesday. The firm’s 50-day moving average is $1.64 and its two-hundred day moving average is $2.30. Alaunos Therapeutics has a 1 year low of $0.72 and a 1 year high of $4.50.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has an average rating of “Sell”.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc is a biotechnology company focused on developing genetically engineered T-cell therapies for cancer. The company has concentrated on T-cell receptor (TCR) therapies designed to recognize and attack tumor-specific mutations, with an emphasis on treating solid tumors that can be difficult to address with conventional immunotherapies.

The company’s research platform has included the Sleeping Beauty gene-transfer system, a nonviral technology intended to introduce therapeutic T-cell receptors into a patient’s own T cells.